Premium
Novel 5‐Methyl‐2‐[(un)substituted phenyl]‐4‐{4,5‐dihydro‐ 3‐[(un)substituted phenyl]‐5‐(1,2,3,4‐tetrahydroisoquinoline‐2‐yl)pyrazol‐1‐yl}‐oxazole Derivatives: Synthesis and Anticancer Activity
Author(s) -
Liu Xinhua,
Bai Linshan,
Pan Chunxiu,
Song Baoan,
Zhu Hailiang
Publication year - 2009
Publication title -
chinese journal of chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.28
H-Index - 41
eISSN - 1614-7065
pISSN - 1001-604X
DOI - 10.1002/cjoc.200990329
Subject(s) - chemistry , oxazole , stereochemistry , tetrahydroisoquinoline , epidermoid carcinoma , in vitro , proton nmr , cell culture , cancer cell lines , cancer cell , basal cell , cancer , biochemistry , medicine , biology , genetics , pathology
Eleven novel 5‐methyl‐2‐[(un)substituted phenyl]‐4‐{4,5‐dihydro‐3‐[(un)substituted phenyl]‐5‐(1,2,3,4‐tetrahydroisoquinoline‐2‐yl)pyrazol‐1‐yl}‐oxazole derivatives were synthesized and characterized by elemental analysis, ESI‐MS, 1 H NMR and 13 C NMR. All of the compounds have been screened for their antiproliferative activities against PC‐3 cell (human prostate cancer) and A431 cell (human epidermoid carcinoma cancer) lines in vitro . The results revealed that compounds 4g , 4j and 4k exhibited the strong inhibitory activities against the PC‐3 cell lines (with IC 50 values of 2.8±0.11, 3.1±0.10 and 3.0±0.06 μg/mL, respectively).